Singlera Genomics specializes in liquid biopsy technology for early cancer detection, utilizing methylation detection methods to assess cancer risk and monitor treatment response. The company addresses the challenge of late-stage cancer diagnosis by providing non-invasive genetic testing solutions for various high-incidence cancers.
Funding
$44.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Late-stage cancer diagnosis significantly reduces treatment options and survival rates. Traditional cancer screening methods often lack the sensitivity to detect tumors at early, more treatable stages, particularly for high-incidence cancers. The need for invasive biopsies for diagnosis and monitoring also presents risks and discomfort for patients.
Solution
Singlera Genomics develops liquid biopsy tests for early cancer detection and monitoring, utilizing advanced methylation detection technology. Their non-invasive blood tests analyze circulating tumor DNA to identify cancer risk, diagnose tumors at earlier stages, guide medication selection, and monitor recurrence. By detecting cancer signals in blood samples, Singlera Genomics aims to improve patient outcomes through earlier intervention and personalized treatment strategies. Their comprehensive range of products and solutions covers cancer early screening, diagnosis, and prognostic monitoring for a variety of cancers such as lung cancer, colorectal cancer, liver cancer, gastric cancer, esophageal cancer, pancreatic cancer, and thyroid cancer.
Target Audience
The primary target audience includes individuals at high risk for cancer, patients undergoing cancer treatment, and healthcare providers seeking advanced diagnostic tools for early cancer detection and personalized medicine.
Features
- Methylation detection technology for analyzing circulating tumor DNA in blood samples
- Non-invasive liquid biopsy approach, eliminating the need for traditional biopsies
- Early cancer detection for improved treatment outcomes
- Risk assessment for individuals at high risk of developing cancer
- Medication guidance based on tumor genetic profiles
- Recurrence monitoring to detect cancer relapse early